We use cookies for a better user experience. Read our Privacy Policy

I Agree

Dementia Associated with Alzimer’s Disease Market

Dementia Associated with Alzimer’s Disease Market [Drug Class: Cholinergic/ Cholinesterase (ChE) Inhibitors, Memantine, and Combined Drug (Memantine & Donepezil) and Others; Distribution Channel: Hospital Pharmacies, Retail, and Online Sales] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018-2026

Dementia Treatment Market - Snapshot

The dementia associated with Alzheimer’s disease market is expected to reach a market value of about US$ 6,936.8 Mn by the end of 2026, expanding at a single digit CAGR during the forecast period. Rise in R&D expenditure, increased prevalence of Alzheimer’s across the globe, increased geriatric population, rise in awareness regarding neurodegenerative diseases in developing countries, and rich pipeline of innovative treatment options are expected to boost the dementia associated with Alzheimer’s disease market during the forecast period. Moreover, increasing research and development activities in disease modifying drugs and surge in investment by key players in the clinical studies of advanced treatment options are expected to propel the dementia associated with Alzheimer’s disease market during the forecast period. However, the high cost of advanced treatments and severe side-effects associated with certain treatments are expected to hamper the dementia associated with Alzheimer’s disease market.

global dementia associated with alzheimer's disease market

The global dementia associated with Alzheimer’s disease market has been segmented based on drug class and distribution channel. In terms of drug class, the global market has been classified into cholinergic/ cholinesterase (ChE) inhibitor, memantine, and combined drug (memantine & donepezil) and others. The cholinergic/ cholinesterase (ChE) inhibitor segment dominates the dementia associated with Alzheimer’s disease market, in terms of value, as it is first line of treatment for AD and most widely prescribed drug for the treatment of AD. This segment is also expected to expand at a significant CAGR, owing to its effectiveness in the treatment of mild to severe dementia. Currently, there is no disease modifying treatment available for Alzheimer’s, and the only approved treatment for the symptomatic relief of AD are cholinesterase inhibitors (Aricept, and memantine. The memantine segment is expected to expand at a notable CAGR, owing to its ability to treat moderate to severe AD and its suitability in cholinergic/ cholinesterase (chE) inhibitors intolerant patients suffering from AD.

In terms of distribution channel, the dementia associated with Alzheimer’s disease market has been segregated into hospital pharmacies, retail, and online sales. The hospital pharmacies segment held a major share of the market in 2017, followed by retail. The hospital pharmacies segment is expected to maintain its market share during forecast period due to availability of cost-effective medications for the treatment of AD. The online pharmacies segment is projected to expand at a considerable CAGR during the forecast period, owing to easy availability of drugs at home at a discounted price and long-term treatment required for the treatment of Alzheimer’s disease.

In terms of geography, the dementia associated with Alzheimer’s disease market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the dementia associated with Alzheimer’s disease market owing to high awareness regarding Alzheimer’s disease in the U.S. and increased prevalence of AD in the region. According to the World Alzheimer’s Report, Alzheimer’s is the sixth-leading cause of death in the U.S. and currently, more than 5 million Americans are living with Alzheimer’s. Rising incidence of Alzheimer’s in elderly age group and demand for advanced therapies and disease modifying drugs is a major factor driving the market in North America. The market in Asia Pacific is projected to expand at a significantly high CAGR during the forecast period, owing to improving health care infrastructure and rising awareness regarding Alzheimer’s in countries such as China and India.

Major players operating in the dementia associated with Alzheimer’s disease market include Merz Pharma GmbH & Co. KGaA., Novartis AG, Allergan plc., Pfizer, Inc., Daiichi Sankyo Company, Limited, Ono Pharmaceutical Co., Ltd, Johnson & Johnson Services, Inc., Eisai Co., Ltd., H. Lundbeck A/S, and F. Hoffmann-La Roche Ltd. Key players are expanding their product portfolios through mergers & acquisitions and partnerships & collaborations with leading pharmaceutical and biotechnology companies and by offering technologically advanced products.

Dementia Associated with Alzheimer’s Disease Market - Snapshot

Alzheimer's is the most common cause of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Alzheimer's disease accounts for 60-80% of dementia cases. Dementia associated with Alzheimer's disease is not a normal part of aging. The greatest known risk factor is increasing age, and the majority of people with Alzheimer's are 65 and older. But dementia associated with Alzheimer's disease is not just a disease of old age. Alzheimer's worsens over time. Alzheimer's is a progressive disease, where dementia symptoms gradually worsen over a number of years. In its early stages, memory loss is mild, but with late-stage Alzheimer's, individuals lose the ability to carry on a conversation and respond to their environment. Alzheimer's is the sixth leading cause of death in the United States. On average, a person with Alzheimer's lives four to eight years after diagnosis, but can live as long as 20 years, depending on other factors.

Dementia associated with Alzheimer's disease has no current cure, but treatments for symptoms are available and research continues. Although current Alzheimer's treatments cannot stop Alzheimer's from progressing, they can temporarily slow the worsening of dementia symptoms and improve quality of life for those with dementia associated with Alzheimer's disease and their caregivers. Today, there is a worldwide effort under way to find better ways to treat the disease, delay its onset, and prevent it from developing. The most common early symptom of Alzheimer's is difficulty remembering newly learned information.

The most common early symptom of Alzheimer's is difficulty remembering newly learned information because Alzheimer's changes typically begin in the part of the brain that affects learning. As Alzheimer's advances through the brain it leads to increasingly severe symptoms, including disorientation, mood and behavior changes. Signs of dementia associated with Alzheimer’s disease may be more obvious to family members or friends. Anyone experiencing dementia-like symptoms should see a doctor as soon as possible.

The global dementia associated with Alzheimer’s disease market has been segmented as below:

Drug Class

  • Cholinergic/ Cholinesterase (ChE) Inhibitors
  • Memantine
  • Combined Drug (Memantine & Donepezil) and Others
  •  

Distribution Channel

  • Hospital Pharmacies
  • Retail
  • Online Sales
  •  

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • GCC Countries
    • Rest of Middle East & Africa

    1. Preface
         1.1. Market Definition and Scope
         1.2. Market Segmentation
         1.3. Key Research Objectives
         1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Dementia Associated with Alzheimer's Disease Market 

    4. Market Overview
         4.1. Introduction
                4.1.1. Drug Class Definition
                4.1.2. Industry Evolution / Developments
         4.2. Overview
         4.3. Market Dynamics
                4.3.1. Drivers
                4.3.2. Restraints
                4.3.3. Opportunities
         4.4. Global Dementia Associated with Alzheimer's Disease Market Analysis and Forecast, 2016–2026
                4.4.1. Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Projections
         4.5. Porter’s Five Force Analysis

    5. Market Outlook
         5.1. Disease Prevalence & Incidence Rate Globally with Key Countries
         5.2. Pipeline Analysis

    6. Global Dementia Associated with Alzheimer's disease Market Analysis and Forecast, by Drug Class
         6.1. Introduction & Definition
         6.2. Key Findings / Developments
         6.3. Global Dementia Associated with Alzheimer's disease Market Value Forecast, by Drug Class, 2016–2026
                6.3.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
                         6.3.1.1. Donepezil 
                         6.3.1.2. Galantamine
                         6.3.1.3. Rivastigmine
                6.3.2. Memantine 
                6.3.3. Combined Drug (Memantine & Donepezil) and Others
         6.4. Global Dementia Associated with Alzheimer's disease Market Attractiveness, by Drug Class

    7. Global Dementia Associated with Alzheimer's disease Market Analysis and Forecast, by Distribution Channel 
         7.1. Introduction & Definition
         7.2. Key Findings / Developments
         7.3. Global Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
                7.3.1. Hospital Pharmacies
                7.3.2. Retail 
                7.3.3. Online Sales 
         7.4. Global Dementia Associated with Alzheimer's Disease Market Attractiveness, by Distribution Channel 

    8. Global Dementia Associated with Alzheimer's Disease Market Analysis and Forecast, by Region
         8.1. Key Findings
         8.2. Global Dementia Associated with Alzheimer's Disease Market Value Forecast, by Region
                8.2.1. North America 
                8.2.2. Europe 
                8.2.3. Asia Pacific 
                8.2.4. Latin America 
                8.2.5. Middle East & Africa 
         8.3. Global Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country/Region

    9. North America Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
         9.1. Introduction
                9.1.1. Key Findings
         9.2. North America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2016–2026
                9.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
                         9.2.1.1. Donepezil 
                         9.2.1.2. Galantamine
                         9.2.1.3. Rivastigmine
                9.2.2. Memantine 
                9.2.3. Combined Drug (Memantine & Donepezil) and Others
         9.3. North America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
                9.3.1. Hospital Pharmacies
                9.3.2. Retail 
                9.3.3. Online Sales 
         9.4. North America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country, 2016–2026
                9.4.1. U.S.
                9.4.2. Canada 
         9.5. North America Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis 
                9.5.1. By Drug Class
                9.5.2. By Distribution Channel 
                9.5.3. By Country

    10. Europe Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
         10.1. Introduction
                10.1.1. Key Findings
         10.2. Europe Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2016–2026
                10.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
                         10.2.1.1. Donepezil 
                         10.2.1.2. Galantamine
                         10.2.1.3. Rivastigmine
                10.2.2. Memantine 
                10.2.3. Combined Drug (Memantine & Donepezil) and Others
         10.3. Europe Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
                10.3.1. Hospital Pharmacies
                10.3.2. Retail 
                10.3.3. Online Sales 
         10.4. Europe Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country/Sub-region, 2016–2026
                10.4.1. Germany
                10.4.2. France
                10.4.3. U.K.
                10.4.4. Italy
                10.4.5. Spain
                10.4.6. Rest of Europe
         10.5. Europe Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis 
                10.5.1. By Drug Class
                10.5.2. By Distribution Channel 
                10.5.3. By Country/Sub-region

    11. Asia Pacific Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
         11.1. Introduction
                11.1.1. Key Findings
         11.2. Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2016–2026
                11.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
                         11.2.1.1. Donepezil 
                         11.2.1.2. Galantamine
                         11.2.1.3. Rivastigmine
                11.2.2. Memantine 
                11.2.3. Combined Drug (Memantine & Donepezil) and Others
         11.3. Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
                11.3.1. Hospital Pharmacies
                11.3.2. Retail 
                11.3.3. Online Sales 
         11.4. Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country/Sub-region, 2016–2026
                11.4.1. Japan
                11.4.2. China
                11.4.3. India
                11.4.4. Australia & New Zealand
                11.4.5. Rest of Asia Pacific
         11.5. Asia Pacific Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis 
                11.5.1. By Drug Class
                11.5.2. By Distribution Channel 
                11.5.3. By Country/Sub-region

    12. Latin America Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
         12.1. Introduction
                12.1.1. Key Findings
         12.2. Latin America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2016–2026
                12.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
                         12.2.1.1. Donepezil 
                         12.2.1.2. Galantamine
                         12.2.1.3. Rivastigmine
                12.2.2. Memantine 
                12.2.3. Combined Drug (Memantine &Donepezil) and Others
         12.3. Latin America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
                12.3.1. Hospital Pharmacies
                12.3.2. Retail 
                12.3.3. Online Sales 
         12.4. Latin America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country/Sub-region, 2016–2026
                12.4.1. Brazil
                12.4.2. Mexico
                12.4.3. Rest of Latin America
         12.5. Latin America Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis 
                12.5.1. By Drug Class
                12.5.2. By Distribution Channel 
                12.5.3. By Country/Sub-region

    13. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
         13.1. Introduction
                13.1.1. Key Findings
         13.2. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2016–2026
                13.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
                         13.2.1.1. Donepezil 
                         13.2.1.2. Galantamine
                         13.2.1.3. Rivastigmine
                13.2.2. Memantine 
                13.2.3. Combined Drug (Memantine & Donepezil) and Others
         13.3. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
                13.3.1. Hospital Pharmacies
                13.3.2. Retail 
                13.3.3. Online Sales 
         13.4. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country/Sub-region, 2016–2026
                13.4.1. GCC Countries
                13.4.2. Israel
                13.4.3. South Africa
                13.4.4. Rest of MEA
         13.5. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis 
                13.5.1. By Drug Class
                13.5.2. By Distribution Channel 
                13.5.3. By Country/Sub-region

    14. Competition Landscape
         14.1. Market Player – Competition Matrix (By Tier and Size of companies)
         14.2. Market Share Analysis by Company (2016)
         14.3. Market Footprint Analysis
                14.3.1. By Region
                14.3.2. By Drug Class Type
         14.4. Competitive Business Strategies
         14.5. Company Profiles
                14.5.1. Merz Pharma GmbH & Co. KGaA 
                         14.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.1.2. Product Portfolio
                         14.5.1.3. SWOT Analysis
                         14.5.1.4. Financial Overview
                         14.5.1.5. Strategic Overview
                14.5.2. Novartis AG  
                         14.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.2.2. Product Portfolio
                         14.5.2.3. SWOT Analysis
                         14.5.2.4. Financial Overview
                         14.5.2.5. Strategic Overview
                14.5.3. Allergan plc.
                         14.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.3.2. Product Portfolio
                         14.5.3.3. SWOT Analysis
                         14.5.3.4. Financial Overview
                         14.5.3.5. Strategic Overview
                14.5.4. Pfizer, Inc.  
                         14.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.4.2. Product Portfolio
                         14.5.4.3. SWOT Analysis
                         14.5.4.4. Financial Overview
                         14.5.4.5. Strategic Overview
                14.5.5. Daiichi Sankyo Company, Limited  
                         14.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.5.2. Product Portfolio
                         14.5.5.3. SWOT Analysis
                         14.5.5.4. Financial Overview
                         14.5.5.5. Strategic Overview
                14.5.6. Ono Pharmaceutical Co., Ltd. 
                         14.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.6.2. Product Portfolio
                         14.5.6.3. SWOT Analysis
                         14.5.6.4. Financial Overview
                         14.5.6.5. Strategic Overview
                14.5.7. Johnson & Johnson Services, Inc. 
                         14.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.7.2. Product Portfolio
                         14.5.7.3. SWOT Analysis
                         14.5.7.4. Financial Overview
                         14.5.7.5. Strategic Overview
                14.5.8. Eisai Co., Ltd. 
                         14.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.8.2. Product Portfolio
                         14.5.8.3. SWOT Analysis
                         14.5.8.4. Financial Overview
                         14.5.8.5. Strategic Overview
                14.5.9. H. Lundbeck A/S 
                         14.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.9.2. Product Portfolio
                         14.5.9.3. SWOT Analysis
                         14.5.9.4. Financial Overview
                         14.5.9.5. Strategic Overview
                14.5.10. F. Hoffmann-La Roche Ltd.  
                         14.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                         14.5.10.2. Product Portfolio
                         14.5.10.3. SWOT Analysis
                         14.5.10.4. Financial Overview
                         14.5.10.5. Strategic Overvie

    List of Tables

    Table 01: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 02: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Cholinergic/ Cholinesterase (ChE) Inhibitors, 2016–2026
    Table 03: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 04: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Region, 2016–2026
    Table 05: North America Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Country, 2016–2026
    Table 06: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 07: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, (Cholinergic/ Cholinesterase (ChE) Inhibitors), 2016–2026
    Table 08: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 09: Europe Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 10: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 11: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, (Cholinergic/ Cholinesterase (ChE) Inhibitors), 2016–2026
    Table 12: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 13: Asia Pacific Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 14: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 15: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, (Cholinergic/ Cholinesterase (ChE) Inhibitors), 2016–2026
    Table 16: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 17: Latin America Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 18: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 19: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, (Cholinergic/ Cholinesterase (ChE) Inhibitors), 2016–2026
    Table 20: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 21: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 22: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 23: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, (Cholinergic/ Cholinesterase (ChE) Inhibitors), 2016–2026
    Table 24: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–202

    List of Figures

    Figure 01: Dementia Associated with Alzheimer's Disease Market Size (US$ Mn) and Distribution, by Region, 2018 and 2026
    Figure 02: Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2018(E)
    Figure 03: Dementia Associated with Alzheimer's Disease Market Snapshot
    Figure 04: Dementia Associated with Alzheimer's Disease Market Value Share
    Figure 05: Dementia Associated with Alzheimer's Disease Market Value Share
    Figure 06: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, 2016–2026
    Figure 07: Global Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017
    Figure 08: Global Dementia Associated with Alzheimer's Disease Market Value Share, by Distribution Channel, 2017
    Figure 09: Global Dementia Associated with Alzheimer's Disease Market Value Share, by Region, 2017
    Figure 10: Global Dementia Associated with Alzheimer's Disease Market Value Share Analysis, by Drug Class, 2018 and 2026
    Figure 11: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Cholinergic/ Cholinesterase (ChE)Inhibitor
    Figure 12: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Memantine
    Figure 13: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Combined Drug (Memantine & Donepezil) and Others
    Figure 14: Global Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis, by Drug Class, 2018–2026
    Figure 15: Global Dementia Associated with Alzheimer's Disease Market Value Share Analysis, by Distribution Channel, 2018 and 2026
    Figure 16: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies
    Figure 17: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail
    Figure 18: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Sales
    Figure 19: Global Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis, by Distribution Channel
    Figure 20: Global Dementia Associated with Alzheimer's Disease Market Value Share, by Region, 2018 and 2026
    Figure 21: Global Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis, by Region, 2018–2026
    Figure 22: North America Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
    Figure 23: North America Dementia Associated with Alzheimer's Disease Market Value Share, by Country, 2017 and 2026
    Figure 24: North America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country, 2018–2026
    Figure 25: North America Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017 and 2026
    Figure 26: North America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Drug Class, 2018–2026
    Figure 27: North America Dementia Associated with Alzheimer's Disease Market Value Share, by Animal Type, 2017 and 2026
    Figure 28: North America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Animal Type, 2018–2026
    Figure 29: Europe Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
    Figure 30: Europe Dementia Associated with Alzheimer's Disease Market Value Share, by Country/Sub-region, 2017 and 2026
    Figure 31: Europe Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 32: Europe Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017 and 2026
    Figure 33: Europe Dementia Associated with Alzheimer's Disease Market Attractiveness, by Drug Class, 2018–2026
    Figure 34: Europe Dementia Associated with Alzheimer's Disease Market Value Share, by Distribution Channel, 2017 and 2026
    Figure 35: Europe Dementia Associated with Alzheimer's Disease Market Attractiveness, by Distribution Channel, 2018–2026
    Figure 36: Asia Pacific Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
    Figure 37: Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Share, by Country/Sub-region, 2017 and 2026
    Figure 38: Asia Pacific Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 39: Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017 and 2026
    Figure 40: Asia Pacific Dementia Associated with Alzheimer's Disease Market Attractiveness, by Drug Class, 2018–2026
    Figure 41: Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Share, by Distribution Channel, 2017 and 2026
    Figure 42: Asia Pacific Dementia Associated with Alzheimer's Disease Market Attractiveness, by Distribution Channel, 2018–2026
    Figure 43: Latin America Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
    Figure 44: Latin America Dementia Associated with Alzheimer's Disease Market Value Share, by Country/Sub-region, 2017 and 2026
    Figure 45: Latin America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 46: Latin America Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017 and 2026
    Figure 47: Latin America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Drug Class, 2018–2026
    Figure 48: Latin America Dementia Associated with Alzheimer's Disease Market Value Share, by Animal Type, 2017 and 2026
    Figure 49: Latin America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Animal Type, 2018–2026
    Figure 50: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
    Figure 51: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Share, by Country/Sub-region, 2017 and 2026
    Figure 52: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 53: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017 and 2026
    Figure 54: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Attractiveness, by Drug Class, 2018–2026
    Figure 55: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Share, by Distribution Channel, 2017 and 2026
    Figure 56: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Attractiveness, by Distribution Channel, 2018–2026
    Figure 57: Merz Pharma GmbH & Co. KGaA Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 58: Merz Pharma GmbH & Co. KGaA R&D Expenses, 2016–2017
    Figure 59: Merz Pharma GmbH & Co. KGaA Breakdown of Net Sales, by Region, 2017
    Figure 60: Merz Pharma GmbH & Co. KGaA Breakdown of Net Sales, by Business Segment, 2017
    Figure 61: Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
    Figure 62: Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2017
    Figure 63: Novartis AG Breakdown of Net Sales, by Region, 2017
    Figure 64: Novartis AG Breakdown of Net Sales, by Business Segment, 2017
    Figure 65: Allergan plc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
    Figure 66: Allergen plc. R&D Expenses, 2016–2017
    Figure 67: Allergan plc. Sales and Marketing Expenses, 2017
    Figure 68: Allergan plc. Breakdown of Net Sales, by Business Segment, 2017
    Figure 69: Pfizer, Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2017
    Figure 70: Pfizer, Inc. R&D Expenses and SI&A Expenses (%) 2015–2017
    Figure 71: Pfizer, Inc. Breakdown of Net Sales, by Geography (Essential Health Segment), 2017
    Figure 72: Pfizer, Inc. Breakdown of Net Sales, by Product (%), 2017
    Figure 73: Daiichi Sankyo Company, Limited Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
    Figure 74: Daiichi Sankyo Company, Limited R&D Expenses (US$ Bn), 2016–2017
    Figure 75: Daiichi Sankyo Company, Limited Breakdown of Net Sales, by Region, 2017
    Figure 76: Ono Pharmaceutical Co., Ltd. Research & Development Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2017
    Figure 77: Ono Pharmaceutical Co., Ltd. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
    Figure 78: Ono Pharmaceutical Co., Ltd. Breakdown of Net Sales, by Geography, 2017
    Figure 79: Johnson & Johnson Services, Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
    Figure 80: Johnson & Johnson Services, Inc. Pharmaceutical Products Segment Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
    Figure 81: Johnson & Johnson Services, Inc. Breakdown of Net Sales, by Business Segment, 2017
    Figure 82: Johnson & Johnson Services, Inc. Research & Development Cost, 2015 – 2017 (US$ Bn)
    Figure 83: Eisai Co., Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
    Figure 84: Eisai Co., Ltd. Breakdown of Net Sales, by Business 
    Figure 85: H. Lundbeck A/S Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
    Figure 86: H. Lundbeck A/S Breakdown of Net Sales, by Region, 2017
    Figure 87: H. Lundbeck A/S Research & Development Cost, 2015 – 2017 (US$ Mn)
    Figure 88: F. Hoffmann-La Roche Ltd. Breakdown of Net Sales, by Business Segment, 2017
    Figure 89: F. Hoffmann-La Roche Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
    Figure 90: F. Hoffmann-La Roche Ltd. Research & Development Cost, 2015 – 2017 (US$ Bn

Google translate

Copyright © Transparency Market Research, Inc. All Rights reserved